Refusal of Adjuvant Therapies and Its Impact on Local Control and Survival in Patients with Bone and Soft Tissue Sarcomas of the Extremities and Trunk
Authors:
Open Access
Abstract
Background: In soft tissue or bone sarcomas, multimodal therapeutic concepts represent the standard of care. Some patients reject the therapeutic recommendations due to several reasons. The aim of this study was to assess the impact of that rejection on both prognosis and local recurrence. Methods: Between 2012 and 2019, a total of 828 sarcoma patients were surgically treated. Chemotherapy was scheduled as a neoadjuvant, and adjuvant multi-agent therapy was performed following recommendations from an interdisciplinary tumor board. Radiotherapy, if deemed appropriate, was administered either in a neoadjuvant or an adjuvant manner. The recommended type of therapy, patient compliance, and the reasons for refusal were documented. Follow-ups included local recurrences, diagnosis of metastatic disease, and patient mortality. Results: Radiotherapy was recommended in 407 (49%) patients. A total of 40 (10%) individuals did not receive radiation. A reduction in overall survival and local recurrence-free survival was evident in those patients who declined radiotherapy. Chemotherapy was advised for 334 (40%) patients, 250 (75%) of whom did receive all recommended cycles. A total of 25 (7%) individuals did receive a partial course while 59 (18%) did not receive any recommended chemotherapy. Overall survival and local recurrence-free survival were reduced in patients refusing chemotherapy. Overall survival was worst for the group of patients who received no chemotherapy due to medical reasons. Refusing chemotherapy for non-medical reasons was seen in 8.8% of patients, and refusal of radiotherapy for non-medical reasons was seen in 4.7% of patients. Conclusions: Divergence from the advised treatment modalities significantly impacted overall survival and local recurrence-free survival across both treatment modalities. There is an imperative need for enhanced physician-patient communication. Reducing treatment times, as achieved with hypofractionated radiotherapy and with therapy in a high-volume sarcoma center, might also have a positive effect on complying with the treatment recommendations.Keywords
This publication has 44 references indexed in Scilit:
- Refusal of Curative Radiation Therapy and Surgery Among Patients With CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Adjuvant chemotherapy for colorectal cancer: age differences in factors influencing patients' treatment decisionsPatient Preference and Adherence, 2013
- Refusing TreatmentThe Oncologist, 2013
- Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health AdministrationCancer, 2011
- Refusal of Radiation Therapy and Its Associated Impact on SurvivalAmerican Journal of Clinical Oncology, 2010
- Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre studyThe Lancet Oncology, 2010
- Underuse of Breast Cancer Adjuvant Treatment: Patient Knowledge, Beliefs, and Medical MistrustJournal of Clinical Oncology, 2009
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trialThe Lancet, 2002
- Personal values and cancer treatment refusalJournal of Medical Ethics, 2000
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984